Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Galapagos, Eli Lilly in osteoporosis deal

Galapagos (Euronext:GLPG; LSE:GLPG) and LLY partnered to discover compounds against 12 GLPG targets to treat osteoporosis.

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE